THE BALANCE

Private admissions

Let’s talk about your next step.

Speak with our admissions team about treatment for you or someone you care about.

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager
Abdullah Boulad, Founder & CEO

Prefer to speak with our founder?

Abdullah Boulad · Founder & CEO

Clinical resource

Lyrica (Pregabalin): Dependence, Misuse and Addiction

Pregabalin can cause dependence, withdrawal and addiction, including during prescribed use. Learn about warning signs, breathing risks and individualized care.

Clinically reviewed byDr. Sarah Boss, MD
Stone residence with a swimming pool, lawn and palm trees

Quick Summary

  • Lyrica contains pregabalin; approved uses vary by country. Physical dependence and addiction can occur during prescribed use, but withdrawal alone does not establish addiction.
  • Slow or difficult breathing, inability to wake or a seizure requires emergency help. Alcohol, opioids and other sedating substances can increase risks; suspected overdose needs urgent advice.
  • Planned discontinuation should follow an individualized gradual reduction with the prescriber, with ongoing care for pain, epilepsy, anxiety or addiction as needed. Residential detox is not required for everyone.

Lyrica is a brand of pregabalin, a prescription medicine used for specific nerve-pain conditions, epilepsy and, in some countries, generalized anxiety disorder. It can cause physical dependence and addiction, including during prescribed use. Understanding these different risks helps people seek appropriate care without assuming that everyone who takes the medicine has an addiction.

Pregabalin is a Schedule V controlled substance in the United States; legal classifications vary elsewhere. Physical dependence means that reducing or stopping treatment can cause withdrawal. Addiction involves impaired control and continued use despite harm. Dependence does not inevitably become addiction, and neither is a reason to change a prescription without a clinical plan.

If someone has slow or difficult breathing, cannot be awakened or has a seizure, call the local emergency number immediately. Pregabalin overdose and combinations with other sedating substances can be dangerous. Suspected overdose needs urgent poison-service or emergency advice, even before severe symptoms develop.

Approved uses depend on country, formulation and age. The US Lyrica label covers specified neuropathic pain conditions, fibromyalgia and add-on treatment for partial-onset seizures. In the UK and EU, adult indications include peripheral and central neuropathic pain, add-on treatment for partial seizures and generalized anxiety disorder. Insomnia is not a general approved indication. Pregabalin is not an opioid, and its dose and monitoring must take kidney function and other medicines into account.

Possible concerns that should be discussed with a clinician include:

  • Taking pregabalin without a prescription, in higher amounts or more often than directed
  • Craving the medicine or repeatedly seeking extra supplies
  • Unsuccessful attempts to control use
  • Continuing use despite associated harm
  • Problems meeting important responsibilities because of medicine use

These concerns need a clinical assessment. Weight changes, sleep problems, memory difficulties or changes in self-care can have other causes and do not prove addiction. Tolerance or withdrawal alone also does not establish addiction. Seek help promptly if control over use is becoming difficult or use is causing harm.

Dependence and addiction can occur during short- or long-term treatment at recommended doses. Some circumstances call for closer monitoring, but they do not predict what will happen to every individual:

People receiving prescribed treatment

A prescription does not remove the possibility of dependence or addiction. Take pregabalin as directed, discuss benefits and adverse effects at medication reviews, and ask the prescriber about concerns or a plan for eventually reducing treatment. Treatment for epilepsy may need to continue as long as clinically necessary.

People in custodial settings

People in custodial settings need access to appropriate prescribed care and assessment if misuse is suspected. Addiction should not be inferred from someone’s setting or social circumstances. A clinician should consider the person’s medicine use, health and support needs.

People with a history of substance use disorder

A current or past substance use disorder can increase risk and should be discussed openly with the prescriber. It does not mean that pregabalin will inevitably cause addiction or that appropriate care should be withheld.

People with mental health conditions

Mental health conditions, including major depression, may call for closer monitoring. Anxiety or insomnia should be assessed rather than self-treated by increasing pregabalin. Care should address both the reason for prescribing it and any difficulties with medicine use.

Withdrawal can follow a dose reduction or stopping, and its severity and duration vary. There is no reliable universal one- or two-week recovery timetable. Symptoms may reflect withdrawal, recurrence of the treated condition or another illness, so clinical review is important.

For planned discontinuation, agree a gradual reduction with the prescriber and adjust it to symptoms and clinical needs. Seizures or severe confusion need emergency assessment. Suicidal thoughts need urgent assessment; immediate danger or inability to stay safe requires emergency help. Reported withdrawal symptoms include:

  • Insomnia
  • Anxiety or agitation
  • Nausea or diarrhea
  • Headache
  • Sweating
  • Tremor
  • Pain or other changes in mood or well-being

Care starts with a physical and mental health assessment, a review of other medicines and substances, and a discussion of the person’s goals. Withdrawal management may be appropriate, but it is not simply drug clearance and does not by itself treat addiction. A residential detox program is not required for everyone.

Clinicians should plan gradual dose reductions and review symptoms, pain, anxiety, epilepsy and other treatment needs. The setting and monitoring depend on individual risk. A fixed withdrawal program or abrupt self-directed stopping may be unsafe.

The medicines discussed below are not an established standard pregabalin withdrawal regimen. Any additional medicine requires an individual assessment of benefits, harms and interactions.

Clonidine

Clonidine is not an established routine treatment for pregabalin withdrawal. Any off-label use requires specialist assessment and monitoring.

Dexmedetomidine

Dexmedetomidine is a sedative requiring continuous monitoring because it can lower blood pressure and heart rate. It is not a routine next step after clonidine for pregabalin withdrawal.

Sleeping Aids

Insomnia is a reported withdrawal symptom of Lyrica. Treatment should be individualized; trazodone or another sedating medicine should not be assumed to be a routine or risk-free withdrawal treatment.

Miscellaneous

Other medicines may be appropriate for a separately assessed symptom or condition, but there is no universal combination of medicines for pregabalin withdrawal.

When addiction is present, continuing care can address impaired control, other substance use, mental health and practical support needs. Treatment can begin during a supported reduction when appropriate; there is no mandatory detox-first sequence. The level of care should be agreed after an individual assessment.

Inpatient Treatment

Inpatient or residential treatment provides care in a supervised setting and may be appropriate for significant medical, psychiatric or other support needs. Program length, staffing and treatment options vary. It is not a universal one- to three-month requirement, and no program guarantees recovery.

Outpatient Treatment

Outpatient care allows the person to remain at home while attending appointments and receiving agreed monitoring and support. Suitability depends on medical and psychiatric risks, other substance use, available support and treatment needs. Psychological care, when indicated, can help with coping skills and difficulties linked to medicine use.

Continuing care and follow-up should be based on ongoing needs rather than a universal one-year limit. This can include medication review, support for mental health and other substance use, and help with daily responsibilities. Plans should be reviewed as circumstances change.

Questions

Frequently Asked Questions

Can Lyrica make you high?
Euphoria has been reported with pregabalin, including in clinical trials. This does not mean that everyone experiences it or develops addiction. Using it for this effect or increasing the dose can be dangerous; discuss any concerns about cravings or control over use with a clinician.
Why is pregabalin addictive?
Pregabalin can cause addiction and physical dependence, including during prescribed use. These are distinct: withdrawal reflects physical adaptation, while addiction involves impaired control and continued use despite harm. Its US Schedule V classification is a legal category, not a prediction of an individual’s risk.
How long does it take to develop Lyrica addiction?
There is no reliable timetable. Dependence and addiction can occur with short- or long-term treatment at recommended doses, and risk depends on the person and circumstances. New cravings, extra use or difficulty controlling use should prompt a medication review.
How long does pregabalin stay in the body?
Pregabalin is eliminated mainly unchanged through the kidneys. Its average half-life is about 6.3 hours in people with normal kidney function; impaired kidney function can prolong elimination. Half-life is not a measure of complete drug clearance or how long withdrawal will last.
Can I mix Lyrica with other substances?
Alcohol, opioids, benzodiazepines and other sedating substances can increase impairment or breathing risks. Avoid alcohol and discuss all medicines and substances with the prescriber or pharmacist. Some combinations are used under clinical supervision; do not alter prescribed treatment on your own. Slow breathing or inability to wake is an emergency.
What are some common side effects of taking Lyrica?
Common effects include dizziness, drowsiness, blurred vision, dry mouth, swelling, weight gain and difficulty concentrating. Avoid driving or hazardous tasks if affected. For swelling of the face, lips, tongue or throat, or a severe allergic reaction, stop the medicine and seek urgent emergency care. Suicidal thoughts need urgent assessment, and immediate danger requires emergency help.

Editorial evidence

Evidence & sources

Selected clinical guidelines, peer-reviewed research, and public-health sources used in this article.

01FDA: Lyrica prescribing information, revised April 2025View source
03MHRA: Dependence, addiction, withdrawal and tolerance information, January 2026View source
View all 8 sourcesShow fewer sources
04MHRA: Pregabalin and severe respiratory depressionView source
07NICE: Medicines associated with dependence or withdrawal symptomsView source
08NIDA: Drugs, brains and behaviour — the science of addictionView source
What this includes
01

Clinical context

Clear information is framed around complex and co-occurring presentations.

02

Individual factors

Assessment remains essential because needs and risks differ from person to person.

03

Next steps

A confidential conversation can help clarify the most appropriate route forward.

Not sure where the situation fits?

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager

A confidential first conversation can help clarify the presentation and whether our setting is appropriate.

THE BALANCE
A PLACE TO BEGIN

Ask about our care